Genex Pharmaceutical, Inc.
GENX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.79K
Close$
Share Statistics
| Market cap | $1,788.00 |
|---|---|
| Enterprise Value | $530,320.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.02 |
| Beta | -0.43 |
| Outstanding Shares | 17,845,732 |
Return
| Return on Equity | 7.23% |
|---|---|
| Return on Assets | 3.96% |
| Return on Invested Capital | 12.81% |
Valuation & Multiples
| P/E Ratio | 0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | 0.8 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.81 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genex Pharmaceutical, Inc.
86 employees
CEO: Fuzhi Song Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company was founded on February 28, 2002 and is headquartered in Tianjin, China.